Zhejiang Medicine's subsidiary plans to build citral project

Summary: On 26 May, 2015, Laiyi Biotechnology, a subsidiary of Zhejiang Medicine announced that it intended to construct a 3,000 t/a citral project. This move will not only meet Zhejiang Medicine's demand for VA, but also create a new profit growth p...

More from CCM

www.cnchemicals.com